Nephros Inc
NEPH Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$3.63
KIRA · Stoqly’s AI analyst, in plain words
- Nephros Inc had $18.8M of revenue in fiscal 2025, up 32.7% on the year before. Over five years, revenue changed +17.0% a year on average.
- Its operating margin was 6.1%, up 6.1 pts: of every 100 in sales, about 6 is left after running the business.
- Nephros Inc made $1.2M of net profit in fiscal 2025.
Market cap
$40.3M
P/E
22.7x
Revenue
$18.8M
Net income
$1.2M
Free cash flow
—
Operating margin
6.1%
Nephros Inc in 30 seconds · fiscal 2025
Are sales growing?
+32.7%
Yes. Sales grew 32.7% last year.
Does it make a profit?
6.4%
A little. It keeps 6.4% of every sale as profit.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
22.7x
One share costs 22.7 times its yearly profit per share.
What Nephros Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- NEPHROS INC
- CIK
- 0001196298
Nephros Inc · NEPH
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $10.2M | $10.0M | $14.2M | $14.2M | $18.8M |
| Revenue growth | 19.3% | −2.4% | 42.7% | −0.5% | 32.7% |
| Gross margin | 55.1% | 47.4% | 59.0% | 61.6% | 61.9% |
| Operating margin | −31.8% | −43.5% | −11.2% | 0.0% | 6.1% |
| Net income | −$3.9M | −$7.1M | −$1.6M | $0.1M | $1.2M |
| Net margin | −37.8% | −71.2% | −11.1% | 0.5% | 6.4% |
| Diluted EPS | −$0.41 | −$0.73 | −$0.15 | $0.01 | $0.11 |
| Cash | |||||
| Cash from operations | −$1.4M | −$3.2M | $0.8M | −$0.5M | $1.6M |
| Capital expenditure | $0.0M | $0.1M | $0.1M | $0.1M | — |
| Free cash flow | −$1.5M | −$3.4M | $0.8M | −$0.5M | — |
| FCF margin | −14.2% | −33.8% | 5.3% | −3.9% | — |
| Share count change | 10.3% | 2.8% | 0.9% | 2.1% | 3.5% |
| Debt and strength | |||||
| Cash and short-term investments | $7.0M | $3.6M | $4.3M | $3.8M | $5.4M |
| Debt incl. finance leases | $0.4M | $0.1M | — | — | — |
| Shareholders' equity | $11.7M | $5.6M | $8.4M | $8.6M | $10.2M |
| Current ratio | 5.7x | 5.9x | 4.0x | 5.3x | 4.1x |
| Interest coverage | −79.3x | −216.8x | −796.5x | 6.0x | 1,146.0x |
| Returns and quality | |||||
| Return on capital | −50.7% | −168.8% | — | — | — |
| Return on equity | −31.9% | −82.2% | −22.6% | 0.9% | 12.7% |
| Return on tangible equity | −39.2% | −167.4% | −21.8% | 1.0% | 13.1% |
| Piotroski F-score | 4 | 4 | 5 | 5 | 6 |
| Altman Z'' | −17.9 | −38.1 | −34.6 | −34.6 | −26.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nephros Inc · NEPH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.63 a share, the company is worth $40.3M: 22.7 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001196298). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.